Jointly provided by
Support for this activity has been provided through educational grants from Amgen; Celgene Corporation; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Takeda Oncology.
Release date: 6/8/2017
Expiration date: 6/8/2018
Estimated time to complete: 1.0 hour
The multiple myeloma clinical landscape has evolved significantly, with not only 10 new drugs but also new staging standards (ie, the R-ISS), imaging techniques, and maintenance therapy options added in the last 12 years. To help hematologist-oncologists keep pace with these advancements and to illustrate their optimal use in practice, this Virtual Practice reviews two multiple myeloma patient cases and invites learners to help determine the best strategies for their care. Also featured is the Resource Library, which houses materials that will be useful to your practice.
A. Keith Stewart, MBChB, MRCP, FRCPC, MBA—Program Chair
Carlson and Nelson Endowed Director
Center for Individualized Medicine
Vasek and Anna Maria Polak Professor of Cancer Research
Consultant, Division of Hematology/Oncology
Faith E. Davies, MBBCh, MRCP, MD, FRCPath
Professor of Medicine
Medical Director, Myeloma Institute
University of Arkansas for Medical Sciences
Little Rock, Arkansas
Thierry Facon, MD
Professor of Haematology
Department of Haematology
Lille University Hospital
This activity has been designed to meet the educational needs of hematologist-oncologists, medical oncologists, and other health care providers involved in the care of patients with multiple myeloma.
Upon completion of this activity, participants should be able to:
- Evaluate current clinical evidence on tools used to define patient prognosis and risk stratification
- Factor the indicated uses, mechanisms of action, and safety of newly available therapies when determining treatment plans for patients with multiple myeloma
- Select treatment combinations in the frontline and salvage settings to achieve the most durable response while balancing the risk for toxicities
Accreditation and Credit Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine, RedMedEd, and the Multiple Myeloma Research Foundation. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Penn State College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In accordance with the ACCME Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of everyone in a position to control content of an educational activity. A relevant financial relationship is a relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears below:
Keith Stewart, MBChB, MRCP, FRCPC, MBA, has disclosed the following relevant financial relationships:
Consultant/Advisor: Bristol-Myers Squibb, Celgene, Novartis
Speakers Bureau: Bristol-Myers Squibb
Faith E. Davies, MBBCH, MRCP, MD, FRCPath, has disclosed the following relevant financial relationships:
Consultant/Advisor: Celgene, Takeda Millennium
Thierry Facon, MD, has disclosed the following relevant financial relationships:
Consultant/Advisor: Amgen, Bristol-Myers Squibb, Celgene, Janssen, Novartis, Takeda
Speakers Bureau: Celgene, Janssen
Penn State College of Medicine
Faculty and staff involved in the development and review of this activity have disclosed no relevant financial relationships.
Multiple Myeloma Research Foundation
Mary DeRome, Director of Medical Communications and Education, has disclosed the following relevant financial relationship:
Anne Quinn Young, MPH, Vice President of Development & Strategic Partnerships, has disclosed no relevant financial relationships.
Denise C. LaTemple, PhD, Director of Scientific Services, has disclosed no relevant financial relationships.
Jonathan S. Simmons, ELS, Senior Managing Editor, has disclosed no relevant financial relationships.
Karen Smith, Creative Director, has disclosed no relevant financial relationships.
Karen Tenaglia, Project Manager, has disclosed no relevant financial relationships.
Barbara Zosh, Director of Operations, has disclosed no relevant financial relationships.
Unapproved Product Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Penn State College of Medicine; RedMedEd; the Multiple Myeloma Research Foundation; Amgen; Celgene Corporation; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Takeda Oncology do not recommend the use of any agent outside the labeled indications.
The information presented at this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Penn State College of Medicine; RedMedEd; the Multiple Myeloma Research Foundation; Amgen; Celgene Corporation; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; or Takeda Oncology. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Method of Participation
There are no fees to participate in the activity. Participants must review all activity information, including the learning objectives, disclosure statements, and content. To receive CME credit for participation, participants must complete the posttest (achieving a passing grade of 80% or greater) and program evaluation. Certificates can be printed immediately.
For questions regarding CME credit, contact Penn State Continuing Education at (717) 531-6483 or ContinuingEd@hmc.psu.edu. Please reference activity code G5998-17-T.
- Apple iPad or iPad mini (iOS 8 or higher) with an Internet connection
- A computer with an Internet connection
- Internet browser (PC): Google Chrome, Internet Explorer 9 or higher, or Firefox 26 or higher
- Internet browser (Mac): Google Chrome, Firefox 26 or higher, or Safari 5 or higher
- Additional software: Adobe Flash Player and/or an HTML 5-capable browser is required for video or audio playback; Adobe Acrobat Reader may occasionally be required
© 2017. This CME-certified program is held as copyrighted by Penn State College of Medicine and RedMedEd. Through this notice, Penn State College of Medicine and RedMedEd grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owners.